-
Media Release
Novartis presents results from first global registration trial of CTL019 in pediatric and young adult patients with r/r B-ALL
-
Media Release
New analysis of Novartis' Entresto® data shows long-term benefits on heart failure readmissions and total cardiovascular deaths
-
Media Release
New analysis of Novartis' Entresto® data shows long-term benefits on heart failure readmissions and total cardiovascular deaths
-
Media Release
Alcon introduces new AIR OPTIX® plus HydraGlyde monthly replacement contact lenses at the American Academy of Optometry annual meeting
-
Media Release
Alcon introduces new AIR OPTIX® plus HydraGlyde monthly replacement contact lenses at the American Academy of Optometry annual meeting
-
Media Release
Novartis partners with prominent US health advocacy organizations to launch first social networking platform for heart failure patients and their loved ones
-
Media Release
Novartis partners with prominent US health advocacy organizations to launch first social networking platform for heart failure patients and their loved ones
-
Media Release
Novartis late-breaking data show Cosentyx® continues to deliver high skin clearance for majority of psoriasis patients at four years
-
Media Release
Novartis late-breaking data show Cosentyx® continues to deliver high skin clearance for majority of psoriasis patients at four years
-
Media Release
Novartis receives three new FDA approvals for the expanded use of Ilaris for patients with rare Periodic Fever Syndrome conditions
-
Media Release
Novartis receives three new FDA approvals for the expanded use of Ilaris for patients with rare Periodic Fever Syndrome conditions
-
Media Release
Important new analysis shows that Novartis' Entresto® is associated with higher relative health-related quality of life scores among HFrEF patients